Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher D Lao

Showing results (1-10 of 86) with videos related to

Pageof 9
Sort By:
Annals of Translational Medicine|October 3, 2019
Immunotherapy for mucosal melanomaSarah Yentz, Christopher D Lao
Current Treatment Options in Oncology|September 3, 2004
Strategies for prevention of colorectal cancer: pharmaceutical and nutritional interventionsChristopher D Lao, Dean E Brenner
Expert Review of Anticancer Therapy|December 1, 2006
Targeting events in melanoma carcinogenesis for the prevention of melanomaChristopher D Lao, Marie-France Demierre, Vernon K Sondak
Pigment Cell & Melanoma Research|December 17, 2010
V559A and N822I double KIT mutant melanoma with predictable response to imatinib?Kevin McDonnell, Bryan Betz, Douglas Fullen, et al.
The New England Journal of Medicine|October 11, 2008
Case 19-2008: Merkel-cell carcinomaSandra L Wong, Christopher D Lao, Christopher K Bichakjian
The Oncologist|July 13, 2016
Management of Adverse Events Following Treatment With Anti-Programmed Death-1 AgentsJeffrey S Weber, Michael Postow, Christopher D Lao, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 6, 2022
Current State of Adjuvant Therapy for Melanoma: Less Is More, or More Is Better?Christopher D Lao, Nikhil I Khushalani, Christina Angeles, et al.
Immunotherapy|April 13, 2022
Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathyVincent T Ma, Christopher D Lao, Leslie A Fecher, et al.
JAMA Oncology|September 25, 2015
Use of Preoperative PET/CT Staging in Sentinel Lymph Node-Positive MelanomaBenjamin Y Scheier, Christopher D Lao, Kelley M Kidwell, et al.
Frontiers in Oncology|October 10, 2022
Treatment related toxicities with combination BRAF and MEK inhibitor therapy in resected stage III melanomaMorgan Homan, Govind Warrier, Christopher D Lao, et al.
Pageof 9

Showing results (1-10 of 86) with videos related to

Sort By:
Pageof 9
Annals of Translational Medicine|October 3, 2019
Immunotherapy for mucosal melanomaSarah Yentz, Christopher D Lao
Current Treatment Options in Oncology|September 3, 2004
Strategies for prevention of colorectal cancer: pharmaceutical and nutritional interventionsChristopher D Lao, Dean E Brenner
Expert Review of Anticancer Therapy|December 1, 2006
Targeting events in melanoma carcinogenesis for the prevention of melanomaChristopher D Lao, Marie-France Demierre, Vernon K Sondak
Pigment Cell & Melanoma Research|December 17, 2010
V559A and N822I double KIT mutant melanoma with predictable response to imatinib?Kevin McDonnell, Bryan Betz, Douglas Fullen, et al.
The New England Journal of Medicine|October 11, 2008
Case 19-2008: Merkel-cell carcinomaSandra L Wong, Christopher D Lao, Christopher K Bichakjian
The Oncologist|July 13, 2016
Management of Adverse Events Following Treatment With Anti-Programmed Death-1 AgentsJeffrey S Weber, Michael Postow, Christopher D Lao, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 6, 2022
Current State of Adjuvant Therapy for Melanoma: Less Is More, or More Is Better?Christopher D Lao, Nikhil I Khushalani, Christina Angeles, et al.
Immunotherapy|April 13, 2022
Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathyVincent T Ma, Christopher D Lao, Leslie A Fecher, et al.
JAMA Oncology|September 25, 2015
Use of Preoperative PET/CT Staging in Sentinel Lymph Node-Positive MelanomaBenjamin Y Scheier, Christopher D Lao, Kelley M Kidwell, et al.
Frontiers in Oncology|October 10, 2022
Treatment related toxicities with combination BRAF and MEK inhibitor therapy in resected stage III melanomaMorgan Homan, Govind Warrier, Christopher D Lao, et al.
Pageof 9